MedTrace Logo

Study of Pembrolizumab and Olaparib in Bile Duct Cancer

NCT04306367 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2025-02-17

Study results available
· View outcomes & findings →

Summary

The investigators propose an open label, one-arm study to assess the safety and efficacy of olaparib and pembrolizumab in patients with cholangiocarcinoma who have progressed on or cannot tolerate gemcitabine-based therapy.

Conditions

Interventions

DRUG

Pembrolizumab

200 mg given intravenously.

DRUG

Olaparib

300 mg given orally.

Sponsors & Collaborators

  • Georgetown University

    lead OTHER

Principal Investigators

  • John Marshall, MD · Georgetown University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2023-07-16
Completion
2024-12-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04306367 on ClinicalTrials.gov